Clinical Investigations in the Treatment of Urothelial Carcinoma

Co-Host: Yair Lotan, MD At the conclusion of these activities, participants will be able to: 1. Explain the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and describe current clinical trial designs. 2. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies. CME Available: auau.auanet.org/node/26083 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma